SBIR/STTR Research Award

Developing a paper-based diagnostic test for sickle cell disease

Award identifier 16ec9cbae5841ce29c17912ac793ad6c76475d33b351c31518cf7db7c03c856bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$449,770

Program and phase

SBIR · Phase I

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
HALCYON BIOMEDICAL INC
Proposal award date
2014-08-06
Contract end date
2016-05-31
UEI
C15ACBHQ4P67
Solicitation number
HL14-010
Topic code
NHLBI

Research abstract

DESCRIPTION provided by applicant Sickle cell disease SCD is the most common hemoglobinopathy associated with significant life long morbidity and premature mortality Over children are born with SCD in sub Saharan Africa annually more than of them die in early childhood Most of these deaths could be prevented through simple and inexpensive prophylaxis if SCD was diagnosed soon after birth Universal screening of newborns is impractical in low income countries due to a large number of out of hospital births and the prohibitive cost of conventional testing methods A simple inexpensive sensitive and specific point of care POC device is therefore urgently needed to enable testing infants and young children during their first visit to a local clinic To address this unmet need we recently developed an ultra low cost paper based test for SCD Our test enables highly accurate diagnosis of SCD through simple visual interpretation of the pattern of the stain produced on chromatography paper by a droplet of blood mixed with hemoglobin Hb solubility buffer By running the assay in a paper substrate and using the natural color of Hb for visual discrimination we eliminated factors that interfere with conventional Hb solubility tests while gaining the capacity to accurately distinguish normal sickle trait and SCD samples ii reducing the required sample volume andlt microL iii lowering the per test cost andlt $ and iv simplifying the interpretation of results In a recent clinical study we validated our test for adlts and children andgt months old The test was able to detect the presence of sickling HbS with sensitivity and specificity demonstrating a positive predictive value of and overall diagnostic accuracy of even for patients with severe anemia Hb andlt g dL This Phase I project will focus on expanding the applicability of paper based SCD test to infants andlt months old and developing a diagnostic kit for deploying the paper based SCD test in the field We will optimize the test to increase its sensitivity for HbSandlt and investigate whether HbFandgt present in younger infants and common co morbidities such as severe anemia hyperlipidemia elevated total protein and malaria have any effect on the diagnostic accuracy of the test We will develop a sample preparation procedure utilizing low cost plastic components to enable a disposable kit determine the range of operating conditions and complete the studies required for regulatory approval of the test by the FDA A successful diagnostic kit will have the number of components number of operations and cost per test not to exceed those of existing solubility assays and be able to detect the presence of HbS in samples from infants and young children with andgt sensitivity and positive predictive value and andgt overall diagnostic value This project represents a crucial step toward the development of a low cost point of care diagnostic test for SCD that could have a potentially transformative impact on the health and well being of tens of thousands of infants and young children worldwide PUBLIC HEALTH RELEVANCE Most children born with sickle cell disease in sub Saharan Africa die in early childhood from causes that could be easily prevented through simple and inexpensive prophylaxis if their disease was diagnosed soon after birth Universal screening of newborns is impractical in low income countries due to a large number of out of hospital births and the prohibitive cost of conventional testing methods This highly innovative project plans to develop and commercialize an ultra low cost paper based diagnostic test for sickle cell disease to enable screening infants and young children during their first visit to a local clinic End of Abstract

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (1992–2020). Reported award amounts total $3,696,303. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.